Journal of Surgical Research
Volume 164, Issue 1 , Pages e61-e66 , November 2010

XRCC1 Gene Polymorphism for Prediction of Response and Prognosis in the Multimodality Therapy of Patients with Locally Advanced Rectal Cancer

  • Peter P. Grimminger, M.D.

      Affiliations

    • Department of General, Visceral, and Cancer Surgery, University of Cologne, Cologne, Germany
    • ,
  • Jan Brabender, M.D.

      Affiliations

    • Department of General, Visceral, and Cancer Surgery, University of Cologne, Cologne, Germany
    • ,
  • Ute Warnecke-Eberz, Ph.D.

      Affiliations

    • Department of General, Visceral, and Cancer Surgery, University of Cologne, Cologne, Germany
    • ,
  • Kosuke Narumiya, M.D.

      Affiliations

    • Department of General, Visceral, and Cancer Surgery, University of Cologne, Cologne, Germany
    • ,
  • Christoph Wandhöfer, M.D.

      Affiliations

    • Department of General, Visceral, and Cancer Surgery, University of Cologne, Cologne, Germany
    • ,
  • Uta Drebber, M.D.

      Affiliations

    • Department of Pathology, University of Cologne, Cologne, Germany
    • ,
  • Elfriede Bollschweiler, M.D.

      Affiliations

    • Department of General, Visceral, and Cancer Surgery, University of Cologne, Cologne, Germany
    • ,
  • Arnulf H. Hölscher, M.D., F.R.C.S., F.A.C.S.

      Affiliations

    • Department of General, Visceral, and Cancer Surgery, University of Cologne, Cologne, Germany
    • ,
  • Ralf Metzger, M.D.

      Affiliations

    • Department of General, Visceral, and Cancer Surgery, University of Cologne, Cologne, Germany
    • ,
  • Daniel Vallböhmer, M.D.

      Affiliations

    • Department of General, Visceral, and Cancer Surgery, University of Cologne, Cologne, Germany
    • Corresponding Author InformationTo whom correspondence and reprint requests should be addressed at Department of General, Visceral, and Cancer Surgery, University of Cologne, Kerpenerstrasse 62, 50937 Cologne, Germany.

Received 1 March 2010

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225
  2. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: A pooled analysis. Int J Radiat Oncol Biol Phys. 2002;54:386
  3. Mohiuddin M, Marks J, Marks G. Management of rectal cancer: Short- vs. long-course preoperative radiation. Int J Radiat Oncol Biol Phys. 2008;72:636
  4. Read TE, McNevin MS, Gross EK, et al. Neoadjuvant therapy for adenocarcinoma of the rectum: Tumor response and acute toxicity. Dis Colon Rectum. 2001;44:513
  5. Janjan NA, Khoo VS, Abbruzzese J, et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys. 1999;44:1027
  6. Kim JS, Kim JS, Cho MJ, et al. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2002;54:403
  7. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731
  8. Chang HJ, Jung KH, Kim DY, et al. Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol. 2005;36:364
  9. Esposito G, Pucciarelli S, Alaggio R, et al. P27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer. Ann Surg Oncol. 2001;8:311
  10. Giralt J, de las Heras M, Cerezo L, et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: A multicenter, retrospective analysis. Radiother Oncol. 2005;74:101
  11. Lenz HJ, Danenberg KD, Leichman CG, et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site. Clin Cancer Res. 1998;4:1227
  12. McIlwrath AJ, Vasey PA, Ross GM, et al. Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res. 1994;54:3718
  13. Rau B, Sturm I, Lage H, et al. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol. 2003;21:3391
  14. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6:1322
  15. Saw RP, Morgan M, Koorey D, et al. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum. 2003;46:192
  16. Spindler KL, Nielsen JN, Lindebjerg J, et al. Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors. Dis Colon Rectum. 2007;50:1363
  17. Stoehlmacher J, Goekkurt E, Mogck U, et al. Thymidylate synthase genotypes and tumor regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. Cancer Lett. 2008;272:221
  18. Kim JS, Kim JM, Li S, et al. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:195
  19. Spindler KL, Nielsen JN, Lindebjerg J, et al. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys. 2006;66:500
  20. Wood RD, Mitchell M, Sgouros J, et al. Human DNA repair genes. Science. 2001;291:1284
  21. Yu Z, Chen J, Ford BN, et al. Human DNA repair systems: An overview. Environ Mol Mutagen. 1999;33:3
  22. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411:366
  23. Masson M, Niedergang C, Schreiber V, et al. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol. 1998;18:3563
  24. Thompson LH, West MG. XRCC1 keeps DNA from getting stranded. Mutat Res. 2000;459:1
  25. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 1998;58:604
  26. Warnecke-Eberz U, Vallbohmer D, Alakus H, et al. ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J Gastrointest Surg. 2009;13:1411
  27. Fernet M, Hall J. Genetic biomarkers of therapeutic radiation sensitivity. DNA Repair (Amst). 2004;3:1237
  28. Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: Implications for response classification. Ann Surg. 2005;242:684
  29. Thomas M, Rube C, Semik M, et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:1185
  30. Junker K, Langner K, Klinke F, et al. Grading of tumor regression in non-small-cell lung cancer: Morphology and prognosis. Chest. 2001;120:1584
  31. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521
  32. Bollschweiler E. Benefits and limitations of Kaplan-Meier calculations of survival chance in cancer surgery. Langenbecks Arch Surg. 2003;388:239
  33. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457
  34. Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: Good practice and pitfalls. Lancet. 2002;359:1686
  35. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): A multicenter, randomized trial. Lancet. 2009;373:811
  36. Cheng XD, Lu WG, Ye F, et al. The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. J Exp Clin Cancer Res. 2009;28:91
  37. Chung HH, Kim MK, Kim JW, et al. P. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol Oncol. 2006;103:1031
  38. Moullan N, Cox DG, Angele S, et al. Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev. 2003;12:1168
  39. Park YA, Sohn SK, Seong J, et al. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol. 2006;93:145
  40. Cascini GL, Avallone A, Delrio P, et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med. 2006;47:1241
  41. Das P, Skibber JM, Rodriguez-Bigas MA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007;109:1750
  42. Smith FM, Reynolds JV, Kay EW, et al. COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy. Int J Radiat Oncol Biol Phys. 2006;64:466
  43. Ghadimi BM, Grade M, Difilippantonio MJ, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol. 2005;23:1826

PII: S0022-4804(10)00679-7

doi: 10.1016/j.jss.2010.08.002

Journal of Surgical Research
Volume 164, Issue 1 , Pages e61-e66 , November 2010

Article Tools

* Image Usage & Resolution